Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05092373 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
A Phase 1 study of Advanced Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT05092373 is a Phase 1 study of Advanced Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 43 participants, below the 85-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05092373, a Phase 1 study of Advanced Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the abdomen or thorax that have spread to other parts of the body (advanced). Tumor treating fields therapy on this study utilizes NovoTTF systems that are wearable devices that use electrical fields at different frequencies that may help stop the growth of tumor cells by interrupting cancer cells' ability to divide. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tumor treating fields therapy in combination with either cabozantinib, or with nab-paclitaxel and atezolizumab may help control advanced solid tumors involving the abdomen or thorax.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- DRUG Cabozantinib S-malate
- DRUG Nab-paclitaxel
- PROCEDURE Tumor Treating Fields Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05092373
The ClinicalTrials.gov registry entry for NCT05092373 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (49% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT05092373 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05092373 about?
NCT05092373 is a clinical study titled "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax". This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in treating patients with solid tumors involving the abdomen or thorax that have spread to other parts of the body (advanced)....
What is the current status of trial NCT05092373?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-04-29. Estimated completion is 2026-09-01.
What conditions does trial NCT05092373 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma, Advanced Renal Cell Carcinoma, Advanced Ovarian Carcinoma, Advanced Breast Carcinoma, Advanced Endometrial Carcinoma.
What interventions are being tested in trial NCT05092373?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Cabozantinib S-malate (DRUG), Nab-paclitaxel (DRUG), Tumor Treating Fields Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT05092373?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05092373 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RECRUITING · Phase 1
-
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
ACTIVE NOT RECRUITING · Phase 1
-
Siliphos in Advanced Hepatocellular Carcinoma
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.